Amongst the clearest examples of bell-shaped dose response effects in humans treated with TNF receptor agonist antibodies include data from cancer patients treated with BMS-986178 (anti-OX40 mAb), PF-04518600 (anti-OX40 mAb) or mitazalimab (anti-CD40 mAb). This evidence concerns the gene CD40 and cancer.